Join the All of Us Research Program...
The All of Us research program, part of the Precision Medicine Initiative through the National Institutes of Health (NIH), is an...
A Randomized, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg with Anastrozole (Arimidex) 1 mg as Hormonal Treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated with Any Hormonal Therapy (FALCOM)
This research is being done to find out more about the treatment of cancer that has either grown beyond the usual limits of the breast or has spread to areas of the body that are distant to it.
Contact Candace LeBlanc 508-556-5431 or Marcy Kirkpatrick 508-556-5429 for more information.
For more information about this study: